New diabetes drug enters first human tests
NCT ID NCT07570992
First seen May 09, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This study is testing a new experimental medicine called NNC1679-0001 for type 2 diabetes. It is a very early (phase 1) trial to check if the drug is safe and how the body handles it. About 58 healthy volunteers and people with type 2 diabetes will receive a single injection of either the drug or a placebo. The main goal is to see if the drug causes any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical University of Graz
RECRUITINGGraz, 8010, Austria
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NNC1679-0001 (an experimental injectable medicine)
What this could lead to
If this early trial shows the drug is safe, it could lead to a new treatment option for type 2 diabetes.
What could go wrong
This is a very early phase 1 study with only 58 participants. The drug may not work or could have side effects. Many drugs fail at this stage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.